[Therapy of Overactive Bladder (OAB)]

Overview

Journal Urologe A

Specialty Urology

Date 2015 Mar 12

PMID 25758236

Citations 1

Authors

M Kurosch

R Mager

K Gust

M Brandt

H Borgmann

A Haferkamp

Affiliations

Soon will be listed here.

Abstract

Overactive bladder (OAB) is a symptom complex which is present in approximately 17% of the European population. It is observed in the presence or absence of incontinence (wet or dry) and is associated with a high degree of psychological stress as well as high costs for the healthcare system. Myogenic, urothelial and neurogenic factors lead to frequently unknown changes of muscular, neural and connective tissue. For the definition, etiology and diagnostics of the disease the previous continuing medical education (CME) article "Diagnosis of overactive bladder (OAB)" should be consulted. In recent years some improvements have been made in OAB-related research, in terms of pathophysiological models and new pharmacological approaches with the development of new therapeutic agents. Besides classical substances, recently approved agents are increasingly being used for the therapy of OAB. Furthermore, non-pharmaceutical approaches and surgical techniques still play an important role in the therapy of OAB.

Citing Articles

Comprehensive analysis of global research on overactive bladder: A scientometric approach.

Wang L, Deng S, Meng F, Zhang L, Min Z, Li J Front Surg. 2023; 9:1078052.

PMID: 36684181 PMC: 9852494. DOI: 10.3389/fsurg.2022.1078052.

References

Schmidt R, Jonas U, Oleson K, JANKNEGT R, Hassouna M, Siegel S . Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999; 162(2):352-7. View

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V . Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig. 2013; 33(6):429-40. DOI: 10.1007/s40261-013-0084-y. View

Juszczak K, Ziomber A, Wyczolkowski M, Thor P . Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol. 2010; 60(4):85-91. View

Collins V, Daly D, Liaskos M, McKay N, Sellers D, Chapple C . OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int. 2013; 112(7):1018-26. DOI: 10.1111/bju.12266. View

Giglio D, Tobin G . Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009; 83(5):259-69. DOI: 10.1159/000209255. View

Chapple C, Sievert K, MacDiarmid S, Khullar V, Radziszewski P, Nardo C . OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013; 64(2):249-56. DOI: 10.1016/j.eururo.2013.04.001. View

Tincello D, Kenyon S, Abrams K, Mayne C, Toozs-Hobson P, Taylor D . Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012; 62(3):507-14. DOI: 10.1016/j.eururo.2011.12.056. View

Kuo H, Liu H, Yang W . Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol. 2006; 176(2):641-5. DOI: 10.1016/j.juro.2006.03.087. View

Nitti V, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C . OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2012; 189(6):2186-93. DOI: 10.1016/j.juro.2012.12.022. View

10.

Apostolidis A, Gonzales G, Fowler C . Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol. 2006; 50(6):1299-305. DOI: 10.1016/j.eururo.2006.04.006. View

11.

Kessler T, Madersbacher H, Kiss G . Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?. Eur Urol. 2005; 47(5):660-5. DOI: 10.1016/j.eururo.2004.11.005. View

12.

Leng W, Chancellor M . How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005; 32(1):11-8. DOI: 10.1016/j.ucl.2004.09.004. View

13.

Chapple C, Kaplan S, Mitcheson D, Klecka J, Cummings J, Drogendijk T . Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2012; 63(2):296-305. DOI: 10.1016/j.eururo.2012.10.048. View

14.

Haferkamp A, Hohenfellner M . [Intravesical treatment of overactive bladder syndrome]. Urologe A. 2006; 45(10):1283-8. DOI: 10.1007/s00120-006-1178-4. View

15.

Thuroff J, Alken P, Engelmann U, Riedmiller H, Jacobi G, Hohenfellner R . The Mainz pouch (mixed augmentation ileum 'n zecum) for bladder augmentation and continent urinary diversion. Eur Urol. 1985; 11(3):152-60. DOI: 10.1159/000472481. View

16.

Abrams P, Andersson K, Buccafusco J, Chapple C, de Groat W, Fryer A . Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5):565-78. PMC: 1751864. DOI: 10.1038/sj.bjp.0706780. View

17.

Dowson C, Watkins J, Khan M, Dasgupta P, Sahai A . Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2011; 61(4):834-9. DOI: 10.1016/j.eururo.2011.12.011. View

18.

Wuest M, Eichhorn B, Grimm M, Wirth M, Ravens U, Kaumann A . Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther. 2008; 328(1):213-22. DOI: 10.1124/jpet.108.142562. View

19.

Hautmann R, Egghart G, Frohneberg D, Miller K . [The ileal neobladder]. Urologe A. 1987; 26(2):67-73. View

20.

Herschorn S, Barkin J, Castro-Diaz D, Frankel J, Espuna-Pons M, Gousse A . A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013; 82(2):313-20. DOI: 10.1016/j.urology.2013.02.077. View